Properties |
Information |
PhytoCAT-ID |
PhytoCAT-504 |
Phytochemical name or plant extracts |
Cucurbitacin E |
PMID |
25072848 |
Literature evidence |
Collectively, these results suggest that CuE may be a viable compound for developing novel TNBC therapeutics. |
IUPAC name |
[(E,6R)-6-[(8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-8,10,12,15,16,17-hexahydro-7H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate |
Phytochemicals’ class or type of plant extracts |
Triterpenoid |
Source of phytochemicals or plant Extracts |
Hemsleya delavayi |
|
Geographical availability |
China South-Central |
Plant parts |
Tubers |
Other cancers |
Breast cancer |
Target gene or protein |
Cyclin D1, Survivin, XIAP, Bcl-2, Mcl-1, JNK, AKT, ERK |
Gene or Protein evidence |
CuE reduced expression of Cyclin D1, Survivin, XIAP, Bcl2, and Mcl-1 in MDA-MB-468 and SW527, and within MDA-MB-468, CuE significantly increased activation of JNK and inhibited activation of AKT and ERK. |
Target pathways |
NA |
IC50 |
0.05 nM against MCF-7
0.02 nM against MDA-MB-468
0.03 nM against MDA-MB-2311
CuE inhibited the growth of all five TNBC lines in a dose-dependent manner, with the IC50 being about 10–70 nM |
Potency |
Overall, the MDA-MB-468 line appeared to be the most sensitive TNBC cell line in regards to the effects of CuE |
Cell line/ mice model |
MDA-MB-231, MDA-MB-468, SW527, MCF-7 |
Additional information |
Collectively, these results suggest that CuE may be a viable compound for developing novel TNBC therapeutics. |
PubChem ID |
5281319 |
Additional PMIDs |
31132750 25970614 |
Additional sources of information |
https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:50923178-1 |
Safety |
NA |